ENVI Committee adopts a report on the Pharmaceutical Strategy for Europe

The European Parliament's Committee on Environment, Public Health and Food Safety (ENVI) adopted a Pharmaceutical Strategy.

The European Parliament's Committee on Environment, Public Health and Food Safety (ENVI) meetings held on 11-12 October, during which the own initiative report (INI) on a Pharmaceutical Strategy for Europe was adopted. After weeks of negotiations, the MEPs agreed on 35 compromise amendments (originally, 723 amendments were published).

The concerning amendments are:

  • Greater involvement of patients’ organisations in drug development and pharmaceutical research strategies to address unmet therapeutic needs.
  • Assess and review the existing incentives framework and stimulate competition by adapting the regulatory framework.
  • Europe to become worldwide centre of excellence for R&D in emerging, innovative fields of medicine.
  • The importance of aligning the current legislation with scientific progress in the development of therapeutic applications of nuclear medicine.
  • The need for a stable and predictable regulatory environment, limiting administrative burden, safeguarding safe, effective and quality medicines on the EU market.
  • A consistent application and enforcement of the GDPR in all EU Member to build the European Health Data Space and leverage the full potential of real-world-data and access to rare therapies.

On 25 November 2020, the Commission published a Communication on a Pharmaceutical Strategy for Europe, a key tool to ensure that EU’s pharmaceutical policy continues to serve public health. Its goal is to give the EU's pharmaceutical policy a long-term vision: to ensure it is crisis-resilient and sustainable, and to reinforce EU's position as a global leader while ensuring access to affordable medicines for patients.

Date: 22/10/2021 | Tag: | News: 1234 of 1554
All news


More news


More events

Subscribe to the VPH Institute Newsletter


Read all the newsletters of the VPH Institute